App-Quantinova.ai

Do risks with the use of erythropoeitin stimulating agents (ESAs) differ by tumor type? Implications concerning survival and thrombosis based on meta-analysis (MA).

Vineeth Sukrithan - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Solid malignancies

N/A

Recurrent VTE in cancer patients treated with anticoagulation.

Michael Blake Streiff - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

rivaroxaban

Variations between physicians in hospice referrals of advanced cancer patients.

Xiao Wang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Integration of comlementary and integrative medicine into palliative care of patients with advanced cancer.

Ayelet Shai - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Methadone hydrochloride

Association of length of hospice enrollment with regional variation in end-of-life care expenditures.

Shi-Yi Wang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Associations of pre- and post-cancer depression with end-of-life cancer care intensity.

Kathy Cao Doan - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Accuracy of oncologists life-expectancy estimates provided to their advanced cancer patients: Correlates and outcomes.

Jason P Lambden - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Complex association between social support and chemotherapy-related toxicities in older cancer patients.

Armin Shahrokni - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Frailty and inflammatory markers in older adults with cancer.

Tomohiro F. Nishijima - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Racial disparity in late mortality among older early-stage breast cancer survivors (BCS).

Kelly Kenzik - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Computerized tomography (CT) assessed body composition (BC) and physical function in older adults with cancer.

Grant Richard Williams - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Improving mental status evaluation in older adults with cancer: The development of the MHI-13.

Mackenzi Pergolotti - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Influence of the comprehensive geriatric assessment (CGA) in elderly metastatic cancer patients. Analysis from a prospective cohort of 1048 patients.

Rabia Boulahssass - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Solid malignancies

N/A

Tool like receptors as a risk factor for infection and death in cancer elderly patients.

Leuridan Torres - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Participation and response assessment of older adults with advanced cancer treated on phase I trials as compared to middle age and AYA patients: An analysis of 1489 patients.

Ishwaria Mohan Subbiah - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

A feasibility trial of geriatric assessment and integrated care plan for older cancer patients.

Martine Puts - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

A Randomized Study of Geriatric Assessment with Management (GAM) in Older Adults with Cancer.

Allison Magnuson - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Severe drug interactions and potentially inappropriate medication usage in elderly patients with cancer.

Ali Alkan - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Predictors of unplanned hospitalizations among older adults receiving cancer chemotherapy.

Heidi D. Klepin - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

A review of the quality of statistical methods employed for analyzing quality of life data in cancer RCTs.

Andrew Bottomley - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Filters

41730 Abstracts